Introduction
Mitochondria are unique organelles that are crucial for sustaining cellular health through multiple functions, including ATP production via oxidative phosphorylation, metabolic regulation, regulation of apoptosis, and Ca
2+ buffering [
1‐
3]. Neurons are highly specialized cells that, like all cells, are critically dependent on intact mitochondrial function for rapidly responding to changes in energy demand, storing and buffering Ca
2+ and, specifically for neurons, neurotransmission and plasticity [
4‐
7]. Due to the critical importance of mitochondria for multiple key aspects of neuronal function, it is not surprising that mitochondrial dysfunction can have devastating effects on brain function [
8‐
10].
Although cisplatin treatment of neurons in vitro or ex vivo leads to cell death, adult neurons do not massively die after cisplatin treatment in vivo suggesting there is an endogenous protective mechanism in place [
8]. However, long lasting cisplatin treatment leads to neuronal mitochondrial dysfunction, which has severe consequences for brain function including cognition [
8,
11].
Astrocytes release multiple factors that are essential to neuronal development, signaling, metabolism, axonal growth and synaptogenesis [
12‐
16]. Recent evidence indicates an additional way via which astrocytes can contribute to neuronal health is by donating healthy mitochondria to damaged neurons [
17,
18]. Specifically, Wang et al. showed that exposure of rat hippocampal astrocytes and neurons to H
2O
2 or serum deprivation promotes transfer of mitochondria from astrocytes to neurons. Moreover, astrocytes not only function as donor of healthy mitochondria but can also function as recipient of damaged mitochondria. Davis et al. showed that retinal ganglion cell axons routinely shed mitochondria at the optic nerve head to be degraded by astrocytes in vivo. Mitochondrial transfer from one cell type to another is not exclusive to astrocytes and neurons [
19]. For example, we and others have shown that mesenchymal stem cells transfer mitochondria to damaged neuronal stem cells thereby improving stem cell survival and mitochondrial membrane potential in the recipient cells [
20‐
22]. Transfer of mitochondria from one cell to another occurs via multiple mechanisms such as release and uptake of vesicles, transfer via gap junctions, and transfer via F-actin based tunneling nanotubes [
17,
23]. Mitochondrial Rho-GTPase 1 (Miro-1) is a calcium-sensitive adaptor protein that drives movement of mitochondria along microtubules [
24‐
28]. Miro-1 is involved in transferring mitochondria from mesenchymal stem cells to neuronal stem cells [
20,
29], but its contribution to mitochondrial transfer from astrocytes to neurons is unknown.
Multiple neurodegenerative disorders, including Parkinson’s disease, Alzheimer’s disease, and chemotherapy-induced cognitive impairment are associated with neuronal mitochondrial dysfunction [
2,
8‐
10,
30‐
32]. We have shown recently that treatment of mice with the chemotherapeutic drug cisplatin results in synaptosomal mitochondrial dysfunction that causes cognitive deficits [
8]. Cisplatin crosses the blood-brain barrier at levels that are sufficient to cause damage to hippocampal neurons and to neuronal stem cells [
33]. However, cisplatin treatment in vivo does not lead to overt neuronal cell death which could indicate that there are endogenous protective mechanisms, such as mitochondrial transfer by astrocytes, to assist in sustaining neuronal health in conditions of acute danger to adult neurons.
The aim of the current study is to test the hypothesis that astrocytes transfer mitochondria to neurons damaged by cisplatin and thereby improve neuronal function and health in vitro.
Materials and methods
Culture of cortical neuron and astrocytes
Timed-pregnant Long Evans rats (Charles River, Wilmington, MA, USA) were sacrificed and E18 fetuses of both sexes were collected in accordance with Institutional Animal Care and Use Committee-approved protocols.
Cortices were dissected and incubated in 10 ml of dissociation media (81.8 mM Na2So4, 30 mM K2SO4, 5.8 mM MgCl2, 0.25 mM CaCl2, 1 mM Hepes, 20 mM glucose, 0.0001% Phenol Red, 0.16 mM NaOH pH = 7.4) that contained 10 U/mL papain and 5 mg of L-cysteine in total (Worthington, Lakewood, NJ, USA) for 10 min at 37 °C, followed by incubation with 150 mg of trypsin inhibitor (Millipore-Sigma, St. Louis, MO) in 10 ml of dissociation media for 10 min at 37 °C. The cortical tissue was mechanically dissociation in Opti-mem (GIBCO, Carlsbad, CA, USA) with 2.5 M Glucose (GIBCO). Cells were cultured on plates coated with 0.05 mg/ml poly-D-lysine (PDL; Millipore-Sigma) in neurobasal medium (NBM) with 100 U/mL penicillin and 1x B-27 supplement (Invitrogen Carlsbad, CA) at 37 °C and 5% CO2. Neuronal cultures were maintained in NBM with B-27 supplement and media was replaced every 3 days. Cortical astrocytes were grown in DMEM/F12 medium supplemented with 10% fetal bovine serum and 5% of 10,000 units/ ml of penicillin and 10,0000 μg/ml of streptomycin (GIBCO) at 5% CO2 and 37 °C.
Neuronal cells were used for experiments after 12–15 days of culturing in vitro (DIV). To confirm neuronal enrichment, cells were fixed with 4% paraformaldehyde in PBS, treated with 0.25% Triton X-100, blocked in 2% BSA in PBS and stained with anti-Map2 antibody (1:2000); Sigma-Aldrich); anti-GFAP (1:200, Acris, Rockville, MD) and anti-Olig2 (1:400, Abcam, Cambridge, UK) antibody. On DIV12 > 98% of cells were Map2+ and Olig2 and GFAP-negative. Astrocytes were used until the third passage and were > 99% GFAP+.
Astrocyte transfections
Astrocytes were plated in a 6-well plate at 1.5 × 105 cells/well 24 h before transfection. For labeling mitochondria, astrocytes were transfected with 2 μg of pLYS1-FLAG-MitoGFP-HA (Addgene plasmid # 50057) which contains the pore-forming subunit of the mitochondrial calcium uniporter coupled to GFP or a mito-mCherry construct generated by subcloning the targeting sequence of the pLYS1-FLAG-MitoGFP-HA plasmid into the mcherry2-N1 vector (Addgene plasmid # 54517). For Miro-1 knockdown, 5 nmol of Rho-1 siRNA (Qiagen, Germany #SI01401743) was diluted in rnase-free water (provided in kit) to make a 20 μM stock, andAllStars Negative Control Scrambled siRNA (Qiagen #SI03650318) was performed similarly to make a 20 μM stock instructions provided. Astrocytes were transfected with 80 nM of Rho-1 siRNA from a 20 μM stock (Qiagen, Germany #SI01401743) or 80 nM AllStars Negative Control Scrambled siRNA from a 20 μM stock (Qiagen #SI03650318). All transfections were performed using the Astrocyte Transfection kit (Altogen Biosystems, Las Vegas, NV, USA) according to manufacturer’s instructions. Miro-1 knockdown was confirmed by Western blot with anti-Rho1 antibody (Novus Biologicals, Centennial, CO, USA) with GAPDH as control (Abcam) followed detection of bands with enhanced chemoluminescence (GE Healthcare Bio-Sciences, Pittsburgh, PA). Blots were captured in the LAS system using Image Quant software (GE Healthcare Bio-Sciences) for quantification of bands.
Analysis of neuronal survival
Neurons were plated in 96 well plates coated with 0.05 mg/ml PDL at 5 × 104 neurons/well. Viability after exposure to cisplatin (Teva, Petah Tikva, Israel) was quantified using the colorimetric cell viability reagent WST-1 (Millipore-Sigma, #11644807001). To assess the effect of astrocytes on neuronal survival, separate cultures of neurons (1.5 × 105 cells/well in a 6-well plate) and astrocytes (5 × 104 /well in a 6-well plate) were treated with cisplatin for 24 h. Neurons were then labeled with 20 μM CellTracker Blue (CTB; Invitrogen) for 45 min at 37 °C, and washed in serum-free media. Astrocytes (5 × 104 cells/well) were added to the neuronal culture and survival of CTB+ neurons was quantified 17 h later using a Countess II FL automated cell counter (Invitrogen).
Analysis of mitochondrial membrane potential and mitochondrial transfer
Neurons were plated at 1.5 × 10
5 cells/well in a 6-well plate, treated with cisplatin for 24 h, and labeled with 20 μM CellTracker Green (Thermo Fisher). Astrocytes (5 × 10
4 cells/well) were added and co-cultured with the neurons for 17 h. The co-cultures were stained with tetramethylrhodamine methyl ester (TMRM, Invitrogen; 250 nM) for 45 min at 37 °C, or Mitotracker (50 nM, Thermo Fisher, Waltham, MA, USA) for 30 min at 37 °C. As a positive control, neurons were treated with 10 μM carbonilcyanide p-triflouromethoxyphenylhydrazone (FCCP, Sigma-Aldrich), a mitochondrial uncoupler, for 15 min. Cells were collected and TMRM fluorescence intensity of the cell tracker green positive cells was quantified using an Accuri C6 Flow Cytometer (BD Biosciences, San Jose, CA USA). For confocal microscopy, neurons were plated in cell culture imaging dishes (ibidi, Fitchburg, WI, USA), treated with cisplatin, stained with CTB and cultured with or without mito-GFP and cell tracker deep red-labeled astrocytes for 17 h followed by staining with TMRM or Mitotracker. The TMRM was used in sub-quench mode as described previously [
34].
For analysis of mitochondrial transfer, neurons exposed to cisplatin or vehicle were labeled with 20 μM CTB (Thermo Fisher) prior to co-culture with astrocytes. Astrocytes were transfected with either mito-GFP or mito-mCherry prior to exposure to cisplatin followed by labeling with 20 μM Celltracker DeepRed (Thermo Fisher) and co-culture with neurons. Neurons containing an area positive for the mito-GFP or mito-mCherry signal that was larger than 8 pixels were scored as containing astrocyte-derived mitohcondria. The co-cultures were imaged on an SPE Leica Confocal Microscope (Leica Microsystems, Buffalo Grove, IL, USA) with a 63 X or 40 X objective and images were analyzed with LAS X software.
Analysis of mitochondrial bioenergetics
To assess mitochondrial bioenergetics, astrocytes (5 × 10
4 cells/well) were plated in a Seahorse XFe 24 microplate (Seahorse Biosciences/Agilent Technologies, Santa Clara, CA, USA) coated with 0.05 mg/ml PDL and treated with 1 μM cisplatin or vehicle for 24 h. Cells were washed and incubated for 1 h at 37 °C in XF base media (Seahorse Biosciences) supplemented with 11 mM glucose (Sigma-Aldrich), 2 mM glutamine (Sigma Aldrich), and 1 mM pyruvate (Sigma-Aldrich), 2 mM Oligomycin (Sigma-Alrich), 4 mM FCCP, and rotenone/antimycin A (Sigma-Aldrich, 2 mM each) were used with a 3-time repeat of a 2-min mix, 3-min wait, and 2-min measure assay cycle. Oxygen consumption rates were normalized to the total protein content of each well. Basal respiration, maximal respiratory capacity, and spare respiratory capacity were determined as described previously [
20].
Calcium imaging
Functional Ca
2+ imaging on cortical neurons was performed as described previously [
35]. 12 mm circular glass coverslips containing cells were incubated at room temperature for 20 min with the Ca
2+-sensitive dye Fura-2-AM (Invitrogen, 2 μM), dissolved in standard extracellular HEPES-buffered HBSS (known hereafter as extracellular imaging buffer) containing the following (in mM): 140 NaCl, 5 KCl, 1.3 CaCl
2, 0.4 MgSO
4, 0.5 MgCl
2, 0.4 KH
2PO
4, 0.6 NaHPO
4, 3 NaHCO
3, 10 glucose, and 10 HEPES adjusted to pH 7.4 with NaOH and 310 mOsm with sucrose. The coverslip was placed in the recording chamber (ALA scientific Instruments, Farmingdale, NY, USA) mounted on the stage of an inverted Nikon Ti2 microscope and continuously superfused for 5 min at room temperature with extracellular imaging buffer. Fura-2 fluorescence was alternately excited at 340 and 380 nm (12 nm band-pass, 50 ms exposure) at 1 Hz using a Lambda LS Xenon lamp (Sutter Instruments, Novato, CA, USA) and a 10x/NA 0.5 objective or 40x/NA 0.6. The CFI Super Fluor 10X was used to measure the ratio of Fura-2 fluorescence. Emitted fluorescence was collected at 510 nm using a sCMOS pco.edge camera for the entire experimental duration, including the first 5 min wash duration, and the ratio of fluorescence (F340:F380) was calculated. The shift in the ratio of Fura-2 fluorescence between excitation at 340 nm versus 380 nm is used as a readout of changes in intracellular calcium concentration [Ca
2+i]. Baseline recording of F340:F380 ratio without stimulus was completed to obtain an indication of resting [Ca
2+i]. Neurons were stimulated with 20 mM of KCl in the extracellular imaging buffer with continuous superfusion at room temperature. Imaging was analyzed with the NIS Elements software. To identify neurons that did or did not receive astrocytic mitochondria, the Nikon inverted Ti2 microscope with associated A1Rsi-HD confocal system and NIS Elements software was used with the CFI S Plan Fluor ELWD 40XC objective. A single exposure at 576 nm excitation was used to quantify fluorescence within neurons before beginning measurement of F340:F380 ratio.
Data analysis
Data are presented as mean ± SEM of at least 3 independent experiments performed in duplicate or triplicate. For survival analysis and mitochondrial membrane potential analysis, data were normalized to the control of each experiment and replicates were averaged. We used One-way or Two-way analysis of variance (ANOVA) with or without repeated measure followed by Tukey’s correction for multiple comparisons or Sidak’s correction for multiple comparisons according to experimental set up. For mitochondrial transfer analysis, the percentage of neurons that received mitochondria was calculate for each group. We used Student’s t-test or Two-way analysis of variance (ANOVA) without repeated measures followed by Tukey’s correction for multiple comparisons. For calcium imaging, the ratio of fluorescence (F340:F380) was calculated and the ratios at baseline were subtracted from the maximum peak values upon KCl stimulus to calculate change in [Ca2+i]. To calculate Ca2+ clearance, F340:F380 ratios were converted to a 0–1 scale with 1 being the maximum value in response to 20 mM KCl. Then, we quantified the time to return to 20% of baseline by counting the values from 1 (maximum peak) to 20% of the baseline value for each neurons. All analyses were performed using GraphPad Prism 8 (GraphPad Software, La Jolla, CA, USA).
Discussion
Our in vitro findings suggest that astrocytic mitochondrial transfer to neurons may represent an endogenous repair mechanism to counteract the neurotoxic effects of cisplatin treatment. Our evidence indicates that cisplatin reduces neuronal survival and decreases mitochondrial membrane potential in the surviving neurons. We also show that co-culture of cisplatin-treated neurons with astrocytes results in mitochondrial transfer from astrocytes to neurons and this is associated with normalization of survival and mitochondrial membrane potential. Cisplatin altered neuronal Ca2+i levels in cortical neurons, and addition of astrocytes normalized neuronal Ca2+i. Calcium levels were specifically restored in those cisplatin-treated neurons that had received astrocytic mitochondria. Moreover, we show that the Rho-GTPase Miro-1 is essential for the transfer of mitochondria from astrocytes to neurons. SiRNA-mediated knockdown of astrocytic Miro-1 prevented transfer of mitochondria from astrocytes to damaged neurons and prevented the restoration of calcium dynamics in neurons damaged by cisplatin. Collectively, our data support the hypothesis that astrocytes counteract the neurotoxic effects of cisplatin by transfering mitochondria to neurons damaged by cisplatin via a Miro-1-dependent pathway.
The effects of astrocytic mitochondrial transfer have been previously shown in disease models of Alexander’s disease and ischemic stroke [
36,
37]. In our in vitro system, we investigated whether astrocytes could also have a restorative effect on neuronal damage as a result of cisplatin treatment. To that end we pre-incubated neurons with cisplatin which caused a significant decrease in neuronal survival and a reduction in the mitochondrial membrane potential in the surviving neurons, and subsequently co-cultured the surviving neurons with astrocytes. Our data show that astrocytes can repair already existing neuronal damage as a result of cisplatin because co-culture with astrocytes restored neuronal mitochondrial membrane potential and protected against further neuronal death. Platinum compounds directly damage the DNA by forming adducts and this interferes with cell proliferation [
38]. It is likely that DNA adducts are also formed in neurons exposed to cisplatin, but because these cells are post-mitotic, it is not known what the effect on cell function will be. It should be noted that we have shown previously that in vivo, preventing mitochondrial damage is sufficient to prevent cognitive deficits that develop in response to treatment with cisplatin [
8,
39]. Therefore, we propose that mitochondrial toxicity is a key factor in cisplatin-induced damage to neurons.
A structural transport mechanism that has been shown to be involved in intercellular mitochondrial transfer are tunneling nanotubes (TNTs). TNTs are thin non-adherent actin-rich membranous structures with diameters between 50 and 1500 nm that can span long distances of several hundred nm [
17,
18,
20,
22,
40‐
42]. These TNT form direct connections between cells to transport cellular components including cytoplasm, ions, lipid droplets, viral and bacterial pathogens, genetic material and organelles like lysosomes, and last but not least, mitochondria [
17,
43,
44]. Multiple authors have described that the mitochondrial Rho-GTPase-1 protein (Miro-1) is a crucial player in intercellular mitochondrial transfer via TNTs. Miro-1 is an outer mitochondrial membrane protein, that binds to Milton, a kinesin/dynein adaptor protein and this promotes mitochondrial motilit y[
26,
28,
45,
46]. We have now expanded this knowledge by showing that decreasing Miro-1 expression in astrocytes decreased the transfer of mitochondria from astrocytes to damaged neurons. Apparently, astrocytic Miro-1 is required for transfer of astrocyte mitochondria to neurons. This could imply that the formation of TNTs for intercellular transport is executed by astrocytes rather than neurons. Jiang et al. have described that the cyclic ADP ribose hydrolase CD-38 plays an important role in astrocytic mitochondrial transfer [
47]. Inhibition of CD-38 with apigenin significantly reduced astrocytic mitochondrial transfer and it has been suggested that CD-38 may be involved in TNT formation [
48]. Furthermore, in an in vitro myeloma cancer model, myeloma cells were shown to receive mitochondria from non-malignant bone marrow stromal cells through CD-38-dependent tumor-derived formation of TNTs [
48]. However, we have to keep in mind that this phenomenon could be specific for tumor cells.
Our data shows that astrocytes transfer mitochondria to neurons damaged by cisplatin while there is only very limited transfer under control conditions. Similarly, we have reported previously mesenchymal stem cells transfer more mitohcondria to neuronal stem cells (NSCs) damaged by cisplatin than to control NSCs [
20]. Berridge et al. showed that astrocytes transfer more mitochondria to damaged neurons in an ischaemic stroke model in comparison to control [
49]. We hypothesize that astrocytes may repond to a “help” signal that is expressed by damaged neurons leading to the transfer of mitochondria. It has been suggested that acculuation of p53 on damaged mitochondrial membranes and/or the release of Damage-Associated Molecular Patterns (DAMPS) could serve as the “help” signal [
50‐
52]. Further studies are needed to identify which signals initiate the transfer process.
Miro-1 modulates mitochondrial shape in response to cytosolic Ca
2+ stress, a phenomenon which is distinct from fission and fusion [
53]. Additionally, Stephen et al. [
27], have shown that Miro-1 positions mitochondria in areas within the astrocytic processes that are near neuronal synaptic activity where high energy and Ca
2+ modulation is necessary. With this in mind it could be possible that astrocytic Miro-1 could be important for positioning mitochondria for transfer in response to neuronal Ca
2+ changes due to cisplatin damage. It is very well possible that additional activities of astrocytes involved in mitochondrial/cellular health could be of importance as well. However, we specifically observed restoration of [Ca
2+]
i levels in those neurons that actually had received astrocytic mitochondria which implies that mitochondrial transfer plays a crucial role in the restorative effect of astrocytes on neuronal [Ca
2+i] levels and health.
Neuronal Ca
2+ levels are tightly regulated and are critical for many processes in neurons including neurotransmission, depolarization, and synaptic activities. Mitochondria play an important role in controlling Ca
2+ levels by taking up, buffering and releasing cytosolic Ca
2+. Cisplatin can negatively alter Ca
2+ levels such as has been observed in the dorsal root ganglia [
54]. Our findings expand this knowledge by showing that cisplatin leads to dysfunctional cortical neuronal Ca
2+ levels. Abnormalities in resting and KCl-evoked Ca
2+ increases and clearance due to treatment of cortical neurons with cisplatin were reversed in the presence of astrocytes. As mitochondria are important for neuronal Ca
2+ dynamics we suggest that astrocytic mitochondrial transfer is key to normalizing the neuronal mitochondrial network. It remains to be determined whether the normalization of Ca
2+ dynamics results from a direct role of the donated mitochondria in calcium buffering or a secondary effect on other key regulators of calcium homeostatis such as the endoplasmic reticulum (ER), Golgi apparatus, and peroxisomes, or the functioning of ion channels and pumps [
55‐
59]. However, our findings do show that transfer of mitochondria normalizes neuronal Ca
2+ dynamics in neurons damaged by cisplatin.
Our cell survival studies showed that astrocytes are much less sensitive to cisplatin than neurons. RNA-seq data [
60], show that astrocytes have a higher concentration of the mitochondrial polymerase gamma (polγ) in comparison to neurons which is the sole polymerase involved in mitochondrial replication, mutagenesis and repair of mtDNA. Therefore, we suggest that the releatively high activity of polγ in astrocytes may lead to efficient repair of cisplatin adducts which could contribute to the observed astrocytic resiliency. In addition, astrocytes have a higher concentration of the copper tansporters ATP7a and ATP7b in comparison to neurons and other glial cells [
60]. ATP7a and ATP7b are copper transporters that also promote platinum efflux and thereby may contribute to cellular resistance to cisplatin [
61‐
63].
An important translational question still lingers: if astrocytic mitochondrial transfer occurs in the brain after cisplatin treatment, why do patients undergoing chemotherapy still experience neurotoxicity leading to chemotherapy-induced cognitive impairment? One argument could be that the endogenous restorative capacity of astrocytes is no longer sufficient when patients are treated for a long time, which is common for chemotherapy with cisplatin. Indeed, the risk of developing chemobrain increases with duration of treatment [
10,
64‐
67]. Moreover, our preliminary data indicate that exposure of mice to a single round of cisplatin treatment does not induce cognitive deficits, whereas two rounds of cisplatin do induce significant decreases in performance in tests of cognitive function [
8,
68]. Although astrocytes may still prevent the actual death of (non self-renewing) adult neurons, they may may fail to completely restore mitochondrial health. The endogenous protective activity of transferring healthy mitochondria from astrocytes to damaged neurons may also become less efficient in the aging brain. From the literature it is known that the severity of the behavioral neurotoxic effects are correlated with age [
65,
66,
69]. When endogenous protective mechanisms are not sufficient, interventions aimed at restoring mitochondrial health may provide additional help. Indeed, we showed recently that cell therapy with mesenchymal stem cells or a pharmacolgocial intervention with PFT-μ and HDAC6 inhibitor both reverse cisplatin-induced neuronal mitochondrial abnomarlities as well as cognitive impairment in mice [
8,
11,
28,
30,
39,
51,
70].
In conclusion, we propose that astrocytic mitochondrial transfer is an important endogenous protection mechanism against chemotherapy neurotoxicity. Promoting astrocytic mitochondrial transfer could represent interesting therapeutic targets to prevent or treat the devastating effects of chemotherapy on the brain.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.